Decision Points in Adult Ph+ ALL

Decision Points in Adult Ph+ ALL

Exploring New Strategies

View Activity

Activity Features

CME Certified

Downloadable Slides

Expert Discussion

Opinion Poll

prIME Points™

View Activity


This activity is provided by prIME Oncology.

Activity Date

January 29, 2018

January 29, 2019

Activity Overview

Hear from the experts about new treatment strategies in adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), including appropriate use of tyrosine kinase inhibitors, how BCR-ABL mutation influences treatment decisions, and how patient fitness informs therapy selection. Clinical scenarios allow you to compare your treatment decisions with the experts and will provide insight into treatment for your patients with Ph+ ALL.


  • Daniel DeAngelo, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Elias Jabbour, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States


  • Induction therapy regimens in Ph+ ALL
  • Relapsed and refractory Ph+ ALL
  • Treatment of fit vs unfit patients

Target Audience

This activity is intended for hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with acute lymphoblastic leukemia.

Learning Objectives

After completion of this educational activity, participants should be able to:

  • Identify risk factors for relapse in Ph+ ALL, including cytogenetic abnormalities and failure to achieve complete molecular remission
  • Interpret findings from contemporary techniques like qRT-PCR and deep sequencing to better predict outcomes and adjust therapy for patients with Ph+ ALL
  • Select an appropriate therapeutic approach for Ph+ ALL, taking into consideration patient fitness, diagnostic findings, and factors related to hematopoietic stem cell transplantation

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and Disclosure Information


This educational activity is supported by a grant from Takeda Oncology.